Table 4.

Multivariable analyses of overall survival

	Eribulin (n = 91)		Capecitabine (n = 79)
	Hazard ratio (95% CI)	p	Hazard ratio (95% CI)	p
When the NLR was a definitive prognostic factor
Age (≥60 years vs. <60 years)	0.74 (0.44–1.21)	0.24	0.92 (0.53–1.56)	0.76
HR (positive vs. negative)	0.57 (0.32–1.06)	0.08	1.05 (0.52–2.42)	0.89
HER2 (negative vs. positive)	0.87 (0.25–5.44)	0.85	1.08 (0.23–19.3)	0.94
NLR (<3 vs. ≥3)	0.53 (0.30–0.95)	0.03	0.56 (0.32–1.01)	0.05
When inflammatory markers that predicted PFS were also included
Age (≥60 years vs. <60 years)	0.60 (0.35–1.01)	0.06	0.74 (0.41–1.30)	0.3
HR (positive vs. negative)	0.54 (0.30–1.01)	0.06	1.60 (0.73–3.91)	0.25
HER2 (negative vs. positive)	1.05 (0.30–6.69)	0.94	2.34 (0.45–43.1)	0.36
ALC (≥1,500/μL vs. <1,500/μL)	0.72 (0.37–1.40)	0.33	0.57 (0.28–1.18)	0.13
NLR (<3 vs. ≥3)	0.80 (0.42–1.56)	0.51	1.65 (0.61–4.63)	0.32
LMR (≥5 vs. <5)	0.64 (0.35–1.18)	0.15	0.50 (0.27–0.94)	0.03
PLR (<250 vs. ≥250)	0.63 (0.33–1.30)	0.2	0.50 (0.18–1.35)	0.17

ALC absolute lymphocyte count; CRP C-reactive protein; ER oestrogen receptor; HER2 human epidermal growth factor receptor 2; HR hormone receptor; LDH lactate dehydrogenase; LMR lymphocyte-to-monocyte ratio; NLR neutrophil-to-lymphocyte ratio; PFS progression-free survival; PgR progesterone receptor; PLR platelet-to-lymphocyte ratio